未知机构：华创医药心玮医疗25年业绩预告转亏为盈颅内自膨药物支架获NMPA注册受理-20260121

Company and Industry Summary Company: 心玮医疗 (Xinwei Medical) Key Points - 2025 Revenue Forecast: The company expects revenue for 2025 to be between 400 million to 410 million yuan, representing a year-on-year growth of over 43.9% [1] - Profitability Improvement: The company anticipates a pre-tax profit of 80 million yuan in 2025, a significant turnaround from a pre-tax net loss of 12 million yuan in 2024 [1] - Revenue Growth Drivers: The revenue increase is attributed to the collaborative growth of three main product lines: ischemic, hemorrhagic, and interventional pathways. New products and technologies in the ischemic stroke field are being applied, leading to a steady increase in market share for various ischemic stroke products [1] - Commercial Sales Expansion: The company has achieved large-scale commercial sales of intracranial stents in the hemorrhagic stroke sector, with other product sales also experiencing growth. Additionally, sales of interventional pathway products continue to rise, contributing to the overall revenue expansion [1] Additional Insights - Cost Management: The company has effectively controlled sales and administrative costs, leading to a reduction in expense ratios and an improvement in profitability [2] - Product Registration: The application for the self-expanding intracranial drug-eluting stent has been accepted by the NMPA, marking a significant milestone as there are currently no similar products available globally. The company's R&D progress is considered to be at the forefront of the industry [2] - Product Pipeline Expansion: The acceptance of the registration application signifies an enhancement of the company's product pipeline in the treatment of vascular stenosis, with ongoing deepening of technological layout [3]